clinical trial · NCT07436689

Long-Term Open-Label Extension Study of Oral Levosimendan

$TENX →·phase3·enrolling by invitation·n = 800

Pulmonary Hypertension Associated With HFpEFTNX-103

brief summary

The purpose of this study is to provide continued access to treatment with oral levosimendan (TNX-103) and to describe the safety of continued use of TNX-103 in participants with pulmonary hypertension with heart failure with preserved left ventricular ejection fraction (PH-HFpEF) who received TNX-103 in a parent study.

started

Mar 13, 2026

primary completion

Mar 1, 2029

completion

Mar 1, 2029

last updated

Mar 19, 2026

official title

A Multicenter, Open-Label, Long-Term Extension Study for Oral Levosimendan (TNX-103)

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol